MARKET

SBBP

SBBP

Strongbridge
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.690
-0.105
-2.77%
After Hours: 3.790 +0.1 +2.71% 19:20 08/14 EDT
OPEN
3.800
PREV CLOSE
3.795
HIGH
3.980
LOW
3.640
VOLUME
2.21M
TURNOVER
--
52 WEEK HIGH
4.630
52 WEEK LOW
1.430
MARKET CAP
200.57M
P/E (TTM)
-3.7951
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 7 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average SBBP stock price target is 8.14 with a high estimate of 18.00 and a low estimate of 5.00.

EPS

SBBP News

More
Strongbridge Biopharma EPS beats by $0.08, beats on revenue
Strongbridge Biopharma (NASDAQ:SBBP): Q2 Non-GAAP EPS of -$0.12 beats by $0.08; GAAP EPS of -$0.32 misses by $0.08. Revenue of $7.76M (+27.6% Y/Y) beats by
seekingalpha · 08/04 16:32
Strongbridge Biopharma (SBBP) Reports Q2 Loss, Tops Revenue Estimates
Strongbridge Biopharma (SBBP) delivered earnings and revenue surprises of 40.00% and 27.03%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/04 13:05
Strongbridge Biopharma shares are trading higher after the company reported better-than-expected Q2 EPS and sales results.
Benzinga · 08/04 12:04
Strongbridge Biopharma Q2 EPS $(0.12) Beats $(0.21) Estimate, Sales $7.76M Beat $6.00M Estimate
Strongbridge Biopharma (NASDAQ:SBBP) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.21) by 42.86 percent. This is a 50 percent increase over losses of $(0.24) per share
Benzinga · 08/04 11:53
Strongbridge Biopharma plc Reports Second Quarter 2020 Financial Results and Provides Corporate Update
~ Reports KEVEYIS® (dichlorphenamide) Second Quarter 2020 Revenue of $7.8 Million, a 28 Percent Increase Compared to $6.1 Million During Second Quarter of 2019 ~ ~ Company Expects to Report Top-Line Results from the Phase 3 LOGICS Study of RECORLEV™ (levoketo
GlobeNewswire · 08/04 11:30
Strongbridge Biopharma plc to Host Second Quarter 2020 Financial Results Conference Call on August 4, 2020
DUBLIN, Ireland and TREVOSE, Pa., July 28, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant
GlobeNewswire · 07/28 11:30
Will Strongbridge Biopharma (SBBP) Report Negative Q2 Earnings? What You Should Know
Strongbridge Biopharma (SBBP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 07/22 16:32
Strongbridge Biopharma appoints John Johnson as CEO
Strongbridge Biopharma (SBBP +1.3%) announces that John H. Johnson will become the chief executive officer of Strongbridge. Mr. Johnson, who has served as
seekingalpha · 07/07 20:02

Industry

Pharmaceuticals
-0.37%
Pharmaceuticals & Medical Research
-0.38%

Hot Stocks

Symbol
Price
%Change

About SBBP

Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company's commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis. The United States Food and Drug Administration (FDA) has granted orphan drug designation for KEVEYIS. The Company has a clinical-stage pipeline of therapies for endocrine diseases. The Company's lead compounds include COR-003 (levoketoconazole), a cortisol synthesis inhibitor, and COR-005 (veldoreotide), a somatostatin analog (SSA). The Company is studying COR-003 for the treatment of endogenous Cushing's syndrome. It is investigating COR-005 for the treatment of acromegaly. Both COR-003 and COR-005 have received orphan designation from the FDA and the European Medicines Agency (EMA).
More

Webull offers kinds of Strongbridge Biopharma plc stock information, including NASDAQ:SBBP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SBBP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SBBP stock methods without spending real money on the virtual paper trading platform.